Please login to the form below
primary hyperoxaluria type 1
This page shows the latest primary hyperoxaluria type 1 news and features for those working in and with pharma, biotech and healthcare.
Alnylam’s RNAi therapeutic expanded by FDA in advanced primary hyperoxaluria type 1
Alnylam Pharmaceuticals’ label expansion for Oxlumo (lumasiran), an RNAi therapeutic administered via subcutaneous injection, has been approved by the US Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria ... type 1 (PH1) to
Latest news
-
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease
Lumasiran hits its objectives in the 20-patient phase 3 trial, which involved patients aged six and over with primary hyperoxaluria type 1 (PH1), a life-threatening but ultra-rare condition ... type 2 form (PH2) of the disease, which is caused by a
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
